Damon P. Eisen

Damon P. Eisen is a Professor at James Cook University's College of Medicine and Dentistry, specializing in Infectious Diseases and Immunology. His research spans tropical infectious diseases, immunology, and antimicrobial resistance with a particular focus on Staphylococcus aureus infections, biofilm formation, and the role of mannose-binding lectin in immune responses. He has led numerous clinical studies and international collaborations, with significant contributions to understanding sepsis, endocarditis, and tuberculosis.

Dr. Eisen's primary research interests center on bacterial pathogenesis, particularly Staphylococcus aureus and its biofilm-related infections in medical devices. His work explores non-antibiotic therapeutic approaches, including repurposed drugs like aspirin and ticagrelor for managing bacterial infections. He has made significant contributions to understanding the role of the complement system, particularly mannose-binding lectin, in infectious disease susceptibility and outcomes. His research also extends to tropical infectious diseases prevalent in Northern Australia, including bacterial meningitis, tuberculosis, and emerging pathogens.

Analysis of Dr. Eisen's recent publications reveals a strong focus on translational research bridging basic science and clinical applications. His work consistently addresses antimicrobial resistance challenges through innovative approaches, particularly non-antibiotic adjuvant therapies for biofilm-related infections. The research spans microbiology, immunology, pharmacology, and clinical medicine, with growing emphasis on tropical infectious diseases and their unique epidemiological patterns in Northern Australia.

Dr. Eisen has been instrumental in several major clinical trials including the ANTISEPSIS trial examining aspirin's effect on sepsis mortality in older adults. His work has established important clinical guidelines regarding antibiotic timing in bacterial meningitis and contributed significantly to understanding the relationship between respiratory infections and cardiovascular complications. He has led multinational collaborations studying infective endocarditis through the ICE-PCS Investigators consortium.

His laboratory and research team focus on bacterial pathogenesis mechanisms, particularly Staphylococcus aureus biofilm formation and strategies to prevent medical device-related infections. The research group employs molecular biology, microbiology, and clinical epidemiology approaches to develop novel therapeutic strategies that could reduce reliance on traditional antibiotics.